APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitors

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Selected research

Market Outlook & Growth Opportunities

Global PD-1 and PD-L1 Inhibitors Market Outlook and Growth Opportunities 2026

Report ID 174022720430 December 2025191 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitors Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitors Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitors Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.

This report provides an overview of the global PD-1 and PD-L1 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of PD-1 and PD-L1 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1 and PD-L1 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1 and PD-L1 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1 and PD-L1 Inhibitors Segment by Company

Merck

Bristol-Myers Squibb

Roche

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

Merck KGaA

PD-1 and PD-L1 Inhibitors Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1 and PD-L1 Inhibitors Segment by Application

Solid Tumors

Blood-related Tumors

PD-1 and PD-L1 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PD-1 and PD-L1 Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PD-1 and PD-L1 Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PD-1 and PD-L1 Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze PD-1 and PD-L1 Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1 and PD-L1 Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-1 and PD-L1 Inhibitors industry.

Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PD-1 and PD-L1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PD-1 and PD-L1 Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PD-1 and PD-L1 Inhibitors Industry Trends Table 2. PD-1 and PD-L1 Inhibitors Industry Drivers Table 3. PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges Table 4. PD-1 and PD-L1 Inhibitors Industry Restraints Table 5. Global PD-1 and PD-L1 Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PD-1 and PD-L1 Inhibitors Revenue Share by Company (2021-2026) Table 7. Global PD-1 and PD-L1 Inhibitors Sales Volume by Company (L) & (2021-2026) Table 8. Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global PD-1 and PD-L1 Inhibitors Average Price (USD/ml) of Company (2021-2026) Table 10. Global PD-1 and PD-L1 Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global PD-1 and PD-L1 Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global PD-1 and PD-L1 Inhibitors Company, Product Type & Application Table 13. Global PD-1 and PD-L1 Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1 and PD-L1 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PD-1 Inhibitors Table 18. Significant Companies of PD-L1 Inhibitors Table 19. Global PD-1 and PD-L1 Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (L) Table 20. Global PD-1 and PD-L1 Inhibitors Sales Volume by Type (2021-2026) & (L) Table 21. Global PD-1 and PD-L1 Inhibitors Sales Volume by Type (2027-2032) & (L) Table 22. Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Type (2021-2026) Table 23. Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Type (2027-2032) Table 24. Global PD-1 and PD-L1 Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global PD-1 and PD-L1 Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global PD-1 and PD-L1 Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Type (2021-2026) Table 28. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Solid Tumors Table 30. Significant Companies of Blood-related Tumors Table 31. Global PD-1 and PD-L1 Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (L) Table 32. Global PD-1 and PD-L1 Inhibitors Sales Volume by Application (2021-2026) & (L) Table 33. Global PD-1 and PD-L1 Inhibitors Sales Volume by Application (2027-2032) & (L) Table 34. Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Application (2021-2026) Table 35. Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Application (2027-2032) Table 36. Global PD-1 and PD-L1 Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global PD-1 and PD-L1 Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global PD-1 and PD-L1 Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Application (2021-2026) Table 40. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Application (2027-2032) Table 41. Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (L) Table 42. Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2026) & (L) Table 43. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2021-2026) Table 44. Global PD-1 and PD-L1 Inhibitors Sales by Region (2027-2032) & (L) Table 45. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2027-2032) Table 46. Global PD-1 and PD-L1 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global PD-1 and PD-L1 Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Region (2021-2026) Table 49. Global PD-1 and PD-L1 Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Region (2027-2032) Table 51. Global PD-1 and PD-L1 Inhibitors Market Average Price (USD/ml) by Region (2021-2026) Table 52. Global PD-1 and PD-L1 Inhibitors Market Average Price (USD/ml) by Region (2027-2032) Table 53. Global PD-1 and PD-L1 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (L) Table 54. Global PD-1 and PD-L1 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 56. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2026) Table 57. Global PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 58. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2027-2032) Table 59. Global PD-1 and PD-L1 Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global PD-1 and PD-L1 Inhibitors Sales Value Market Share by Country (2021-2026) Table 61. Global PD-1 and PD-L1 Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global PD-1 and PD-L1 Inhibitors Sales Value Market Share by Country (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 66. Merck PD-1 and PD-L1 Inhibitors Product Portfolio Table 67. Merck Recent Development Table 68. Bristol-Myers Squibb Company Information Table 69. Bristol-Myers Squibb Business Overview Table 70. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 71. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio Table 72. Bristol-Myers Squibb Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 76. Roche PD-1 and PD-L1 Inhibitors Product Portfolio Table 77. Roche Recent Development Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 81. AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio Table 82. AstraZeneca Recent Development Table 83. Ono Pharmaceutical Company Information Table 84. Ono Pharmaceutical Business Overview Table 85. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 86. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio Table 87. Ono Pharmaceutical Recent Development Table 88. Regeneron Company Information Table 89. Regeneron Business Overview Table 90. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 91. Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio Table 92. Regeneron Recent Development Table 93. Innovent Company Information Table 94. Innovent Business Overview Table 95. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 96. Innovent PD-1 and PD-L1 Inhibitors Product Portfolio Table 97. Innovent Recent Development Table 98. Hengrui Medicine Company Information Table 99. Hengrui Medicine Business Overview Table 100. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 101. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio Table 102. Hengrui Medicine Recent Development Table 103. Junshi Biosciences Company Information Table 104. Junshi Biosciences Business Overview Table 105. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 106. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio Table 107. Junshi Biosciences Recent Development Table 108. Merck KGaA Company Information Table 109. Merck KGaA Business Overview Table 110. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Value (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 111. Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio Table 112. Merck KGaA Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. PD-1 and PD-L1 Inhibitors Distributors List Table 116. PD-1 and PD-L1 Inhibitors Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. PD-1 and PD-L1 Inhibitors Product Image Figure 2. Global PD-1 and PD-L1 Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1 and PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global PD-1 and PD-L1 Inhibitors Sales (2021-2032) & (L) Figure 5. Global PD-1 and PD-L1 Inhibitors Sales Average Price (USD/ml) & (2021-2032) Figure 6. Global PD-1 and PD-L1 Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PD-1 Inhibitors Image Figure 10. PD-L1 Inhibitors Image Figure 11. Global PD-1 and PD-L1 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (L) Figure 12. Global PD-1 and PD-L1 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Type (2021-2032) Figure 14. Global PD-1 and PD-L1 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global PD-1 and PD-L1 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Type (2021-2032) Figure 17. Solid Tumors Image Figure 18. Blood-related Tumors Image Figure 19. Global PD-1 and PD-L1 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (L) Figure 20. Global PD-1 and PD-L1 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Application (2021-2032) Figure 22. Global PD-1 and PD-L1 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global PD-1 and PD-L1 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Application (2021-2032) Figure 25. Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (L) Figure 26. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global PD-1 and PD-L1 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global PD-1 and PD-L1 Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America PD-1 and PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 30. North America PD-1 and PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe PD-1 and PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 32. Europe PD-1 and PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America PD-1 and PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 36. South America PD-1 and PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. PD-1 and PD-L1 Inhibitors Value Chain Figure 124. Manufacturing Cost Structure Figure 125. PD-1 and PD-L1 Inhibitors Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Solid Tumors
  • Blood-related Tumors
Companies covered
  • Merck
  • Bristol-Myers Squibb
  • Roche
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PD-1 and PD-L1 Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global PD-1 and PD-L1 Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global PD-1 and PD-L1 Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PD-1 and PD-L1 Inhibitors Market Dynamics
  1. 2.1 PD-1 and PD-L1 Inhibitors Industry Trends
  2. 2.2 PD-1 and PD-L1 Inhibitors Industry Drivers
  3. 2.3 PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
  4. 2.4 PD-1 and PD-L1 Inhibitors Industry Restraints
3 PD-1 and PD-L1 Inhibitors Market by Company
  1. 3.1 Global PD-1 and PD-L1 Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global PD-1 and PD-L1 Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global PD-1 and PD-L1 Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global PD-1 and PD-L1 Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global PD-1 and PD-L1 Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global PD-1 and PD-L1 Inhibitors Company Product Type and Application
  8. 3.8 Global PD-1 and PD-L1 Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PD-1 and PD-L1 Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PD-1 and PD-L1 Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PD-1 and PD-L1 Inhibitors Market by Type
  1. 4.1 PD-1 and PD-L1 Inhibitors Type Introduction
  2. 4.1.1 PD-1 Inhibitors
  3. 4.1.2 PD-L1 Inhibitors
  4. 4.2 Global PD-1 and PD-L1 Inhibitors Sales Volume by Type
  5. 4.2.1 Global PD-1 and PD-L1 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1 and PD-L1 Inhibitors Sales Volume by Type (2021-2032)
  7. 4.2.3 Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Type (2021-2032)
  8. 4.3 Global PD-1 and PD-L1 Inhibitors Sales Value by Type
  9. 4.3.1 Global PD-1 and PD-L1 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1 and PD-L1 Inhibitors Sales Value by Type (2021-2032)
  11. 4.3.3 Global PD-1 and PD-L1 Inhibitors Sales Value Share by Type (2021-2032)
5 PD-1 and PD-L1 Inhibitors Market by Application
  1. 5.1 PD-1 and PD-L1 Inhibitors Application Introduction
  2. 5.1.1 Solid Tumors
  3. 5.1.2 Blood-related Tumors
  4. 5.2 Global PD-1 and PD-L1 Inhibitors Sales Volume by Application
  5. 5.2.1 Global PD-1 and PD-L1 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global PD-1 and PD-L1 Inhibitors Sales Volume by Application (2021-2032)
  7. 5.2.3 Global PD-1 and PD-L1 Inhibitors Sales Volume Share by Application (2021-2032)
  8. 5.3 Global PD-1 and PD-L1 Inhibitors Sales Value by Application
  9. 5.3.1 Global PD-1 and PD-L1 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global PD-1 and PD-L1 Inhibitors Sales Value by Application (2021-2032)
  11. 5.3.3 Global PD-1 and PD-L1 Inhibitors Sales Value Share by Application (2021-2032)
6 PD-1 and PD-L1 Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global PD-1 and PD-L1 Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PD-1 and PD-L1 Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global PD-1 and PD-L1 Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global PD-1 and PD-L1 Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global PD-1 and PD-L1 Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PD-1 and PD-L1 Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America PD-1 and PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PD-1 and PD-L1 Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe PD-1 and PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PD-1 and PD-L1 Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America PD-1 and PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Value Share by Country, 2025 VS 2032
7 PD-1 and PD-L1 Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global PD-1 and PD-L1 Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PD-1 and PD-L1 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global PD-1 and PD-L1 Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global PD-1 and PD-L1 Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global PD-1 and PD-L1 Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PD-1 and PD-L1 Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PD-1 and PD-L1 Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PD-1 and PD-L1 Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Ono Pharmaceutical
  26. 8.5.1 Ono Pharmaceutical Company Information
  27. 8.5.2 Ono Pharmaceutical Business Overview
  28. 8.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
  30. 8.5.5 Ono Pharmaceutical Recent Developments
  31. 8.6 Regeneron
  32. 8.6.1 Regeneron Company Information
  33. 8.6.2 Regeneron Business Overview
  34. 8.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
  36. 8.6.5 Regeneron Recent Developments
  37. 8.7 Innovent
  38. 8.7.1 Innovent Company Information
  39. 8.7.2 Innovent Business Overview
  40. 8.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
  42. 8.7.5 Innovent Recent Developments
  43. 8.8 Hengrui Medicine
  44. 8.8.1 Hengrui Medicine Company Information
  45. 8.8.2 Hengrui Medicine Business Overview
  46. 8.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
  48. 8.8.5 Hengrui Medicine Recent Developments
  49. 8.9 Junshi Biosciences
  50. 8.9.1 Junshi Biosciences Company Information
  51. 8.9.2 Junshi Biosciences Business Overview
  52. 8.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
  54. 8.9.5 Junshi Biosciences Recent Developments
  55. 8.10 Merck KGaA
  56. 8.10.1 Merck KGaA Company Information
  57. 8.10.2 Merck KGaA Business Overview
  58. 8.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
  60. 8.10.5 Merck KGaA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
  2. 9.1.1 PD-1 and PD-L1 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1 and PD-L1 Inhibitors Sales Mode & Process
  6. 9.2 PD-1 and PD-L1 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1 and PD-L1 Inhibitors Distributors
  9. 9.2.3 PD-1 and PD-L1 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst